Efficacy observation of adalimumab in the treatment of severe plaque psoriasis
阿达木单抗治疗重度斑块型银屑病疗效观察

摘要

目的 探讨阿达木单抗治疗重度斑块型银屑病的疗效。方法 根据本院2021-04至2022-04这一年中，将收治的重度斑块型银屑病患者，随机抽选76例进行研究，并以数字抽签法对患者进行分组治疗，对照组患者有38例，接受常规西药治疗，另外的观察组，同样有38例，应用阿达木单抗治疗，对2组患者治疗的临床疗效、皮肤状况及不良反应等指标展开对比与分析。结果 通过评估2组患者的不良反应，其观察组患者出现的发热、上呼吸感染及皮肤干燥发生率更低于对照组患者，（P＜0.05）。结论 对于重度斑块型银屑病患者的治疗，临床应用阿达木单抗的疗效确切且安全性高，利于改善患者的皮损状况，促进患者早日康复，值得推广。

Abstract

Objective: To investigate the efficacy of adalimumab in the treatment of severe plaque psoriasis.
Methods: According to the year 2021-04 to 2022-04, 76 patients with severe plaque psoriasis who were admitted to our hospital were randomly selected for research, and the patients were divided into groups by digital lottery method, and the control group There were 38 patients who received conventional western medicine treatment, and 38 patients in the other observation group were also treated with adalimumab. The clinical efficacy, skin conditions and adverse reactions of the two groups of patients were compared and analyzed.
Results: By evaluating the adverse reactions of the two groups of patients, the incidence of fever, upper respiratory infection and dry skin in the observation group was lower than that in the control group (P<0.05).
Conclusion  : For the treatment of patients with severe plaque psoriasis, the clinical application of adalimumab has definite curative effect and high safety.